HZNP News and Press, Horizon Therapeutics Public Limited Company From 06/14/22

UBS has launched its coverage on Horizon Therapeutics (NASDAQ:HZNP) with a Buy recommendation and as the firm’s top pick. Noting a clinical readout next year, the firm argues that the rare-disease-focused biotech is best positioned to accelerate growth through appealing business develo...

-- Data presented at ENDO 2022 indicates l ow rates of hyperglycemic events were easily controlled, did not cause treatment disruption and were most often seen in patients with pre-existing diabetes -- -- A separate poster presentation examined response to TEPEZZA in patie...

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been recognized by Seramount (formerly Working Mother media) as a Top 75 Company for Executive Women . Seramount’s list focuses on women in the corporate officer and profit-and-loss leadership ranks. It t...

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in June: Goldman Sachs 43 rd Annual Global Health Care Conference Date: Tuesday, June 14, 2022 Presentation Time: 11 a.m. ET The conferen...

-- Poster presentation will share results from the Phase 2 and Phase 3 trials on blood glucose levels in patients with Thyroid Eye Disease (TED) -- -- Three-time Olympic gold medalist Gail Devers will discuss her experience living with Graves’ disease and TED at events ...

My portfolio, built specifically for my retirement ~20+ years from now, makes a strong pivot from my formerly diversified base to a more focused core. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping crea...

-- Data through Month 6 showed a greater than 32% increase in patient response rate and infusion reactions were reduced from 31% to 4% -- -- Oral presentation on MIRROR randomized controlled trial to be held at The EULAR 2022 European Congress of Rheumatology on June 2, 2022 a...

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the company has won an International Corporate Social Responsibility (CSR) Excellence Award for its partnership with Gift of Adoption to co-create the #RAREis Adoption Fund. As part of the award, Horizon will be formally recogn...

-- Data being presented at the CMSC Annual Meeting demonstrates UPLIZNA may reduce attack risk and disability among populations with genetic variables typically linked to poor treatment response -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced data from the...

John Paulson’s 13F portfolio value increased marginally from $3.24B to $3.25B this quarter. Paulson & Company added SPDR Gold Trust ETF while reducing Pacira BioSciences and TIM S.A. They also dropped Shell plc and TotalEnergies SE. The top three positions are at 43% of...